Malignant Pleural Mesothelioma

Targeted agents did not demonstrate a significant clinical benefit in mesothelioma treatment, nevertheless a small group of patients might harbor potentially actionable somatic mutations, as in homologous repair recombination genes. In this paper we report two cases of patients with heavily pretreated pleural mesothelioma that had a relevant clinical benefit with rucaparib treatment based on somatic BRCA 1 and BRCA 2 mutations detected through next generation sequencing.

P=N/A, N=240, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Oct 2025 --> Oct 2030 | Trial primary completion date: Jan 2024 --> Jan 2030

P1, N=260, Not yet recruiting, IDEAYA Biosciences

P1, N=20, Recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Dec 2025 --> Feb 2027 | Trial primary completion date: Dec 2025 --> Feb 2027

We also summarize ongoing therapeutic strategies targeting MSLN and discuss how TME-driven resistance mechanisms are shaping the next generation of MSLN-directed therapies. By integrating molecular insights with translational perspectives, this work provides a comprehensive overview of MSLN biology and its emerging therapeutic relevance in cancer.

CD68, CD206, PD-L1, and LOXL3 may collaboratively contribute to the regulation of the PM microenvironment and are closely linked to the invasion and metastasis of PM. Therefore, LOXL3 can be used as both a prognostic marker and a potential therapeutic target for PM.

These findings demonstrate that TA-MUC1 has been documented in diverse malignancies, including rare and metastatic presentations. The descriptive evidence supports its potential relevance as a therapeutic target and highlights the need for standardized evaluation and prospective studies.

These multi-omic, scRNA-seq analyses of primary patient tissues provide new candidate drivers of MC state and novel biomarkers to improve patient stratification. Further experimental exploration and clinical validation of these findings may reveal new treatment strategies and refine current clinical decision-making in pleural mesothelioma.

Circulating miRNA signatures represent promising non-invasive biomarkers for early PM detection and prognostic stratification, particularly in epithelioid cases. Incorporation of these biomarkers into clinical workflows could pave the way for more personalized treatment strategies and optimize patient selection for surgery.

Background/Objectives: Despite the introduction of targeted therapies such as Nivolumab, survival outcomes for patients with esophageal adenocarcinoma remain poor. This underscores the urgent need for clinical trials evaluating the efficacy of pegargiminase in this patient population. Additionally, incorporating ASS1 immunohistochemical staining into pre-neoadjuvant biopsy assessments should be considered to optimize neoadjuvant treatment strategies and advance the implementation of personalized cancer therapy.

During the follow-up period of 224-238 days, the experimental pigs remained in good health.​ Based on the study of differentially expressed proteins in malignant pleural mesothelioma under hypoxic and normoxic conditions, the successfully constructed large-scale porcine tumor model can pre-verify the effect of drugs on tumors in different oxygen environments during new drug development, improving screening efficiency and success rate. It can also accurately simulate clinical scenarios, providing experimental support for the efficacy evaluation and scheme optimization of intervention strategies such as chemotherapy, radiotherapy, and immune targeting, thereby effectively promoting the development of clinical treatment for malignant pleural mesothelioma.​.

P1/2, N=19, Completed, CRISPR Therapeutics AG | Recruiting --> Completed | N=250 --> 19 | Trial completion date: May 2030 --> Sep 2025 | Trial primary completion date: Apr 2030 --> Sep 2025